Drugs / Avutometinib
Avutometinib
also known as
VS-6766 · RO5126766 · avutometinib (VS-6766) · AVUTOMETINIB POTASSIUM · CH5126766 · CH5126766-002 · CKI-27 · R-7304 · +4 more
Small molecule targets MAP2K1, MAP2K2 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | AVMAPKI FAKZYNJA CO-PACK (COPACKAGED) | — | 2025-05-08 | fda.gov ↗ |
Trials 27 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05798507 | Jul 2023 → Dec 2026 expected | glioblastoma | Emory University | Active not recruiting | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT07318324 | May 2026 → Aug 2028 expected | endometrial cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06104488 | Oct 2023 → Oct 2029 expected | carcinoma, low grade glioma, neuroblastoma, neurofibromatosis type 1 +4 | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03681483 | Oct 2018 → Jul 2024 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03875820 | Dec 2017 → Apr 2023 overdue | endometrioid adenocarcinoma, malignant pancreatic neoplasm, non-small cell lung carcinoma, ovarian serous tumor | Institute of Cancer Research, United Kingdom | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02407509 | Jun 2013 → Oct 2025 | lung cancer, ovarian cancer, plasma cell myeloma | Royal Marsden NHS Foundation Trust | Completed | No outcome recorded |
| Phase 1 | NCT00773526 | Nov 2008 → Sep 2011 | neoplasm | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT06630260 | Nov 2024 → Sep 2029 expected | diffuse glioma, H3 G34 mutant, glioblastoma | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06194929 | Mar 2024 → Jan 2028 expected | cutaneous melanoma, metastatic malignant neoplasm in the brain | University of Utah | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05669482 | Mar 2023 → Aug 2026 overdue | malignant pancreatic neoplasm, metastatic malignant neoplasm | Verastem, Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05608252 | Feb 2023 → Dec 2027 expected | hormone receptor-positive breast cancer | Adrienne G. Waks | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05200442 | Aug 2022 → May 2027 | colorectal adenocarcinoma | University of Chicago | Suspended | No outcome recorded |
| Phase 1/2 | NCT05375994 | Aug 2022 → Jun 2026 | metastatic malignant neoplasm, non-small cell lung carcinoma | Verastem, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT05074810 | Apr 2022 → Jun 2026 overdue | non-small cell lung carcinoma | Verastem, Inc. | Active not recruiting | No outcome recorded |
| Phase 212 trials | ||||||
| Phase 2 | NCT07126158 | Apr 2026 → Apr 2030 expected | pancreatic adenocarcinoma | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT06369259 | Feb 2025 → Feb 2029 expected | colorectal cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06682572 | Oct 2024 → Dec 2025 overdue | ovarian cancer, ovarian serous tumor | Verastem, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06487221 | Oct 2024 → Nov 2028 expected | diffuse gastric cancer | Ryan H. Moy, MD, PhD | Recruiting | No outcome recorded |
| Phase 2 | NCT06495125 | Jul 2024 → Mar 2029 expected | lung adenocarcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 2 | NCT06394804 | Apr 2024 → Apr 2027 expected | malignant ovarian serous tumor | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06007924 | Aug 2023 → Aug 2027 expected | thyroid cancer | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05787561 | Mar 2023 → Mar 2027 expected | mesonephric neoplasm | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05512208 | Feb 2023 → Dec 2027 expected | cervical cancer, endometrioid adenocarcinoma, malignant ovarian serous tumor, mucinous ovarian cancer | University of Oklahoma | Recruiting | No outcome recorded |
| Phase 2 | NCT04720417 | Jan 2021 → Apr 2024 | uveal melanoma | Thomas Jefferson University | Terminated | No outcome recorded |
| Phase 2 | NCT04620330 | Dec 2020 → Aug 2023 | non-small cell lung carcinoma | Verastem, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04625270 | Dec 2020 → Nov 2024 overdue | ovarian serous adenocarcinoma | Verastem, Inc. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06072781 | Mar 2024 → Oct 2028 expected | ovarian serous tumor | Verastem, Inc. | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05187169 Comparator | Dec 2021 → Apr 2022 | — | Verastem, Inc. | Completed | No outcome recorded |
Evidence & citations 18 cited values
Every value below carries the sentence it was read from. 29 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | avutometinib | “VS-6766/avutometinib” NCT05200442 ↗ |
| Known as | avutometinib (VS-6766) | “avutometinib (VS-6766)” NCT06072781 ↗ |
| Known as | AVUTOMETINIB POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3264002 ↗ |
| Known as | CH5126766 | “CH5126766” NCT03875820 ↗ |
| Known as | CH5126766-002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3264002 ↗ |
| Known as | CKI-27 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3264002 ↗ |
| Known as | R-7304 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3264002 ↗ |
| Known as | Rg-7304 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3264002 ↗ |
| Known as | RO-5126766 POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3264002 ↗ |
| Known as | RO5126766 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03681483 ↗ |
| Known as | RO5126766-002 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3264002 ↗ |
| Known as | VS-6766 | “This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been...” NCT05375994 ↗14“This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal...” NCT05669482 ↗ “Avutometinib (also known as VS-6766) is an oral drug that blocks an important signaling pathway in cancer cells known as the MAP kinase pathway.” NCT06487221 ↗ “A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer” NCT05787561 ↗ “Avutometinib (VS-6766), a RAF/MEK Clamp in Combination With Defactinib, a FAK Inhibitor” NCT06104488 ↗ “Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week” NCT05512208 ↗ “Avutometinib (VS-6766) (Dual RAF/MEK Inhibitor)” NCT04620330 ↗ “Avutometinib (VS-6766) + Defactinib (VS-6063)” NCT06682572 ↗ “avutometinib (VS-6766)” NCT04625270 ↗ |
| Known as | VS-6766 POTASSIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3264002 ↗ |
| Action | Inhibit | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL3264002 ↗2“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL3264002 ↗ “a Dual Raf and MEK Inhibitor” NCT00773526 ↗ |
| Modality | Small molecule | “VS-6766 is a unique small molecule drug” NCT05608252 ↗ |
| Route | Oral | “Administered orally daily for 28 days” NCT00773526 ↗ |
| Target | MAP2K1 | “Dual specificity mitogen-activated protein kinase kinase 1 inhibitor” CHEMBL3264002 ↗ |
| Target | MAP2K2 | “Dual specificity mitogen-activated protein kinase kinase 2 inhibitor” CHEMBL3264002 ↗ |